GeoVax Receives Notice Of Allowance For Marburg Vaccine Patent; Application Number 17/584,231 Titled "Replication-Deficient Modified Vaccinia Ankara (MVA) Expressing Marburg Virus Glycoprotein (GP) And Matrix Protein (VP40)."
Portfolio Pulse from Benzinga Newsdesk
GeoVax has received a notice of allowance for its Marburg vaccine patent, titled 'Replication-Deficient Modified Vaccinia Ankara (MVA) Expressing Marburg Virus Glycoprotein (GP) And Matrix Protein (VP40)'. The patent application number is 17/584,231.
October 09, 2023 | 1:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
GeoVax's receipt of a notice of allowance for its Marburg vaccine patent could potentially boost the company's stock.
The notice of allowance for GeoVax's Marburg vaccine patent signifies that the patent office believes the company's invention to be novel and non-obvious. This could potentially increase the company's value and, in turn, its stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100